MAPT and Brain atrophy: Today, imaging methods, including structural magnetic resonance imaging (MRI) for visualization of brain atrophy, 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG) PET for measurement of brain metabolism, amyloid-PET for quantification of insoluble Aβ deposits (plaques), Tau-PET [18F] flortaucipir for quantification of pathogenic Tau and CSF biomarkers (CSF Aβ42 and Tau) are recognized as valid diagnostic tools [22, 30].